Doctor of Optometry Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Chad Thompson

Optometrist Beloit, KS Doctor of Optometry

NPI 1609865120 CMS profile 26808

214 N Mill St, Beloit, KS 67420

Open in the dashboard

General payments

$96,309

317 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Chad Thompson of Beloit, KS is reported in the CMS Open Payments database as having received $96,309 across 317 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Optometrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $15,313 60
2024 General $1,108 6
2023 General $2,569 17
2022 General $17,412 73
2021 General $23,910 68
2020 General $6,679 16
2019 General $29,318 77

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Chad Thompson
  • Optometrist median
  • Middle half of Optometrist
  • National median

In program year 2025, general payments to Chad Thompson were reported at $15,313. Among 35,373 Optometrist profiles paid that year, the median was $204 and the middle half received between $87 and $464.

Show as a table
Year Chad Thompson Optometrist median Middle half National median
2019 $29,318 $159 $67–$371 $163
2020 $6,679 $72 $29–$165 $114
2021 $23,910 $125 $46–$292 $132
2022 $17,412 $162 $66–$374 $149
2023 $2,569 $177 $72–$406 $160
2024 $1,108 $188 $77–$427 $164
2025 $15,313 $204 $87–$464 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Alcon Vision LLC $92,111 309 payments
  2. Alcon Research LLC $3,705 2 payments
  3. Optos, Inc. $206 3 payments
  4. Topcon Medical Systems, Inc. $172 2 payments
  5. Bausch & Lomb, a division of Bausch Health US, LLC $115 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $41,215 34 payments
  2. Travel and Lodging $28,758 128 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $20,646 15 payments
  4. Food and Beverage $5,484 137 payments
  5. Entertainment $206 3 payments
Products named General payments · program years 2019–2025
  1. TOTAL30 $36,025 121 payments
  2. DAILIES $29,425 76 payments
  3. DAILIES TOTAL1 $28,716 87 payments
  4. Precision 1 $20,924 69 payments
  5. Precision7 $15,161 59 payments
  6. AIR OPTIX $799 4 payments
  7. OCT OPHTHALMOSCOPE Ophthalmology $206 3 payments
  8. NFC-700 $206 3 payments
  9. OCT OPHTHALMOSCOPE Ophthalmology $206 3 payments
  10. PANORAMIC OPHTHALMOSCOPE $206 3 payments
  11. Other $574 7 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

628

Median for Optometry: 120

Drug cost

$57,155

Median for Optometry: $8,864

Branded share of claims

29.6%

Median for Optometry: 24.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Restasis Cyclosporine Brand 43 $20,582
Lumigan Bimatoprost Brand 31 $11,367
Travoprost Generic 59 $6,156
Loteprednol Etabonate Generic 29 $5,244
Combigan Brimonidine Tartrate/Timolol Brand 17 $3,594
Prednisolone Acetate Generic 88 $3,336
Tobramycin-Dexamethasone Tobramycin/Dexamethasone Brand 37 $2,038
Latanoprost Generic 142 $1,652
Dorzolamide-Timolol Dorzolamide Hcl/Timolol Maleat Brand 46 $1,340
Acetazolamide Generic 11 $583

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 27,653 Part D prescribers listed as Optometry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 20 billing codes

Paid by Medicare

$146,879

Medicare's payments for the services billed

Medicare patients

765

Average age 75

Services billed

2,432

429 women, 336 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 41%
Chronic kidney disease 32%
Diabetes 29%
Depression 22%
Ischemic heart disease 21%
Heart failure 17%
Atrial fibrillation 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

317 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Optometrist in Kansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record